Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fred Hutchinson Cancer Center
OBJECTIVES:
I. To determine whether the incidence of nausea and vomiting related to administration of autologous hematopoetic stem cells cryopreserved in DMSO can be reduced by the use of a single dose of intravenous ondansetron prior to the stem cell infusion.
II. To determine the number of patients who experience nausea and vomiting.
OUTLINE: Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Inclusion
Autologous PBSC transplant patient
English-speaking
Planned cryopreserved PBSC infusion at the SCCA outpatient clinic
Exclusion
History of prior autologous transplant
Non-English-speaking
Planned cryopreserved PBSC infusion at the UWMC inpatient unit
Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion
